ATHOS
Background/Rationale: Isolated systolic hypertension (ISH : SBP>140 mmHg and DBP<90 mmHg) affects predominantly the elderly. Indeed, about 65% of hypertensive patients over 60 years of age have ISH. ISH is associated with an increased risk for cardiovascular events and mortality.
Objective: The objective of the ATHOS study was to compare the effect of PritorPlus®/Kinzalkomb® (telmisartan+HCTZ) with the calcium channel blocker amlodipine in a fixed dose combination with HCTZ in elderly patients with ISH.
Study Design: The ATHOS study was a 14-week, prospective, randomised, open-label, blinded-endpoint (PROBE), multicentre, parallel-group trial in elderly patients with ISH.
Study Endpoints:
- Primary endpoint: Change from baseline in SBP during the last 6 hours of the dosing interval using ABPM.
- Secondary endpoint included the change from baseline in DBP and pulse pressure during the last 6 hours of the dosing interval at Week 14 and changes from baseline in BP over other time periods (24-hour mean, morning mean [6 a.m. tn Il :59 a.m.], daytime mean [6 a.m. to 9:59 p.m.], and nighttime mean [10 p.m. ta 5:59 a.rn.]).
Results:
- PritorPlus®/Kinzalkomb® provides superior SBP reductions over the 24-hour dosing interval and similar early morning SBP reductions in elderly patients with ISH compared with amldodipine/HCTZ.
- PritorPlus®/Kinzalkomb®:Significantly less drug-related adverse events and discontinuation rates than amlodipine/HCTZ.
Neldam S et al. AJGC 2006; 15: 151-160.
Conclusion:
In elderly patients with isolated systolic hypertension, PritorPlus®/Kinzalkomb® offers: - Superior BP reductions throughout the 24-hour dosing interval compared with mlodipine/HCTZ
- Similar BP reductions during the last 6 hours compared with amlodipine/HCTZ
